



Bedrocan

Pharmaceutical-quality cannabis API
& raw materials





About Bedrocan

Bedrocan is the most experienced producer of medicinal cannabis in the world. We are using unique methods of producing cannabis to meet pharmaceutical standards. Our state-of-the-art facilities in the Netherlands and Denmark follow strict quality guidelines and are EU-GMP-certified. We produce cannabis as active pharmaceutical ingredients (API) and raw materials in different varieties and forms. Our products are fully standardised. Each variety, batch to batch, is genetically identical and contains a consistent composition of cannabinoids, the active ingredients in the cannabis plant. Our standardised, pharmaceutical-quality products are used worldwide for the development of high-quality medicinal products, clinical research, and patient treatment in various compassionate programmes where access to medicinal cannabis is provided.

Our method

Bedrocan is an expert in consistently producing cannabis flos with stable cannabinoid content. Each chemovar originates from one single seed, ensuring genetic stability through proprietary propagation techniques. Unlike milling and blending methods that standardise only THC and CBD, our unique approach maintains the full spectrum of active ingredients.

Our facilities in the Netherlands and Denmark operate with precision, controlling every aspect of cultivation, from light, temperature and nutrients to ensuring air quality and absence of pesticides or fungicides. We follow EU good manufacturing practice (GMP) standards, with rigorous quality control measures, including independent lab testing and irradiation for safety. We harvest weekly, 52 weeks a year; every batch is predictable and traceable.

By setting the highest standards in medicinal cannabis production and supply, Bedrocan helps medicine manufacturers with efficient and consistent production planning and a seamless transition within GMP. Additionally, our standardised products assist clinical researchers and healthcare professionals with establishing accurate dosing and optimal clinical safety. Our dedication to science and innovation makes Bedrocan a trusted choice for researchers and healthcare professionals worldwide.



Our team

Contact our business team for orders, customer inquiries, and possible business collaborations.



Karolina Ostapenko

Head of Pharmacy Channel Development



Nino Rakić

Product manager



Our facilities

Bedrocan products are completely grown within fully-controlled indoor environments at our state-of-the-art EU-GMP-certified facilities:

The Netherlands

In the Netherlands, we operate two facilities with a combined capacity of up to 7,500 kg. From these facilities, we have supplied the Dutch Office of Medicinal Cannabis (OMC) medicinal cannabis programme since 2003. Our facilities in the Netherlands can also supply medicine manufacturers.

Denmark

In Denmark, our facility inaugurated in 2025 was built to mirror the Dutch facilities' production standards. The Danish facility has a 2,300 kg capacity and is also EU-GMP-certified. From Denmark, we supply all the medicinal cannabis products in our portfolio to pharmaceutical distributors and medicine manufacturers worldwide.

Canada

Bedrocan also has a branch in Toronto, Canada. This is the same facility Bedrocan operated when it was active in Canada (until 2017). The purchase of the facility in 2023 marks the beginning of a journey to bring Bedrocan products back to Canadian patients who need access to pharmaceutical-quality medicinal cannabis.



Cultivation



Processing



Packaging



Why Bedrocan?

Five reasons why customers around the world have chosen our products:



Over two decades of experience and knowledge



Standardised cannabis with identical genetics and consistent content




Free of microbial contaminants, pesticides and heavy metals



Product forms and orders that can be customised to customers' needs



EU-GMP pharmaceutical-quality API and raw materials



Experience and knowledge

With a rich heritage dating back to 1984, Bedrocan has evolved from cultivating various plants under controlled conditions to pioneering the standardisation of medicinal cannabis. The company stands as the world's most experienced producer of standardised medicinal cannabis, and the first medicinal cannabis company to comply with the European Medicines Agency's good manufacturing practice (GMP) standards.

Our journey is marked by a steadfast commitment to pharmaceutical quality, research, and patient well-being.

Pioneering standardisation

Bedrocan sets itself apart in the medicinal cannabis industry due to its unique capability of producing fully standardised cannabis flowers, with consistent levels of active ingredients, batch-to-batch. This dedication provides medicine developers, medical practitioners and clinical researchers with reliable data on therapeutic effects on patients.

Global Reach

Bedrocan's products are available in multiple countries, including the Netherlands, Australia, Germany, Finland, Israel, Italy, Macedonia, Switzerland, the UK and Poland.

This extensive reach underscores our ability to meet diverse regulatory requirements and patient needs across various regions.



Pharmaceutical quality standards

Bedrocan was the first cannabis company in the world to get an EU-GMP certification for the production of medicinal cannabis in 2017. In cultivation, the company goes beyond the good agricultural and collection practice (GACP) standards. Considering the unique nature of the cultivation of cannabis for medicinal and scientific purposes, Bedrocan created its own guidelines for the cultivation of medicinal cannabis: the **good medicinal cannabis cultivation practice (GMCCP)**. A GMCCP white paper (bedrocan.com/gmccp) has been created in order to advocate for specific standards for the cultivation of medicinal cannabis.



Research

Our commitment to advancing knowledge about medicinal cannabis is evident through our extensive research efforts. Bedrocan has its own Clinical Research Unit where research is conducted into the effects of medicinal cannabis on humans. The Clinical Research Unit is located in the Netherlands and started its first study in 2025. The company also has an R&D facility, where our plant science team conducts research into cannabis genetics and the potential medicinal properties of other plants. Our products have been widely used in research, which is an example of the quality and suitability of our products for scientific purposes.

Check all relevant studies at
bedrocan.com/research



Our products

Product	Form	THC*	CBD*
Bedrocan®	• Flos	22%	< 1%
	• Cut flos	21%	< 1%
	• Industrial	According to required product specifications	
Bedrobinol®	• Flos	13.5%	< 1%
	• Cut flos	13.5%	< 1%
	• Industrial	According to required product specifications	
Bediol®	• Cut flos	6.3%	8.8%
	• Industrial	According to required product specifications	
Bedica®	• Flos	14.4%	< 1%
	• Cut flos	14.4%	< 1%
	• Industrial	According to required product specifications	
Bedrolite®	• Cut flos	< 1%	8.1%
	• Industrial	According to required product specifications	
Bedropuur®	• Flos	20%	< 1%
	• Cut flos	20%	< 1%
	• Industrial	According to required product specifications	
Bedrolina®	• Flos	< 1%	14%
	• Cut flos	< 1%	14%
	• Industrial	According to required product specifications	

* Content subject to +/- 10% deviation.

Bedrocan also supplies raw materials to other companies in the industry for manufacturing a variety of medicinal cannabis products, including extracts, cannabinoid isolates, or other dosage forms tailored to specific patient or market needs. Check our product brochure to learn more about partner products.

With decades of experience and expertise, Bedrocan is committed to exploring new ways to support prescribers and increase patient access to pharmaceutical-grade medicinal cannabis. Our product brochure provides insights into the types and availability of products currently in development.



Compounding technologies

Compounding pharmacies play a crucial role in customising medicinal cannabis products to meet individual patient needs. The medicinal cannabis industry faces challenges related to knowledge, quality control, and dosing standardisation, making it difficult for healthcare providers to ensure consistent and effective treatments. Recognising the importance of personalised medicine, Bedrocan is committed to supporting compounding pharmacies in delivering high-quality, tailored treatments that meet each patient's specific requirements. In recent years, Bedrocan has focused on exploring technologies that facilitate such treatments and has identified methods that ensure more efficient use of the starting material while allowing for more precise dosing of active substances. Please, refer to our Product Brochure for more information on the compounding technologies.

Contract manufacturing

Bedrocan offers contract manufacturing services for the cultivation, drying, processing, and packaging of medicinal cannabis. This service is focused on companies that are interested in maximising the potential of their varieties through the extensive experience and knowledge in the field of cannabis cultivation Bedrocan has gathered in over two decades.

Date of Preparation
April 2025

bedrocan.com

Copyright® 2025 by Bedrocan

All rights reserved. No part of this document may be reproduced, distributed or transmitted in any form or by any means, including photocopying, without the prior written consent of Bedrocan.

Customer experience



At Syqe, we chose Bedrocan for their pharmaceutical-grade cannabis to ensure consistent, reliable treatment for patients. Their commitment to quality aligns with our mission to deliver safe and effective care every time.

Hagit Kamin, CEO, Syqe Medical



DanCann Pharma only works with products prepared according to standards that apply in the manufacture of conventional medicine. Bedrocan's products, which are fully manufactured under GMP, represent the ideal match for the Danish Pilot Programme.

Jeppe Krog Rasmussen, CEO, DanCann



The pharmacy team of Clinical Cannabis Care specializes in advising on cannabis products. This expertise is utilized by its subsidiary Cannadis Europe (EU GMP manufacturer) to produce high-quality and patient-centered products (IMPs and APIs) using only reliable raw materials. Bedrocan has been our supplier for years.

Heleen Kuijper-Tissot van Patot, pharmacist, Clinical Cannabis Care and Cannadis Europe



For Echo Pharmaceuticals, as developer and manufacturer of natural cannabinoid based medicinal products, it is pivotal that the cannabis flowers we use for the isolation of cannabinoids are of the highest quality level. During the last 20 years Bedrocan has proven to supply us reliably with cannabis flowers of consistently high and EU-GMP compliant quality.

Anthony Kievid, Director Business Development, Echo Pharmaceuticals

Join these and other companies worldwide and become one of our satisfied customers. There are many collaboration possibilities. Contact our business team:
business@bedrocan.com

bedrocan.com